CN Patent

CN107531721B — 用于调节法尼醇x受体的稠合的三环吡唑衍生物

Assigned to Novartis AG · Expires 2020-07-17 · 6y expired

What this patent protects

本发明涉及式I的化合物， 其立体异构体、对映体、药学上可接受的盐或氨基酸缀合物；其中变量如本文所定义；且本发明还涉及它们的药物组合物，这些药物组合物用作法尼醇X受体(FXR)活性的调节剂。

USPTO Abstract

本发明涉及式I的化合物， 其立体异构体、对映体、药学上可接受的盐或氨基酸缀合物；其中变量如本文所定义；且本发明还涉及它们的药物组合物，这些药物组合物用作法尼醇X受体(FXR)活性的调节剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN107531721B
Jurisdiction
CN
Classification
—
Expires
2020-07-17
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.